Bone Remodelling Markers in Rheumatoid Arthritis

Fardellone, Patrice; Séjourné, Alice; Paccou, Julien; Goëb, Vincent

Document type :

Compte-rendu et recension critique d'ouvrage

DOI :

10.1155/2014/484280

Title :

Bone Remodelling Markers in Rheumatoid Arthritis

Author(s) :

Fardellone, Patrice [Auteur]
CHU Amiens-Picardie
Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 [MP3CV]
Séjourné, Alice [Auteur]
CHU Amiens-Picardie
Paccou, Julien [Auteur]

Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Université de Lille
CHU Amiens-Picardie
Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 [MP3CV]
Goëb, Vincent [Auteur]
Service de Rhumatologie [CHU Rouen]

Journal title :

Mediators of Inflammation

Pages :

1-5

Publisher :

Hindawi Publishing Corporation

Publication date :

2014

ISSN :

0962-9351

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Bone loss in rheumatoid arthritis (RA) patients results from chronic inflammation and can lead to osteoporosis and fractures. A few bone remodeling markers have been studied in RA witnessing bone formation (osteocalcin), ...
Show more >Bone loss in rheumatoid arthritis (RA) patients results from chronic inflammation and can lead to osteoporosis and fractures. A few bone remodeling markers have been studied in RA witnessing bone formation (osteocalcin), serum aminoterminal propeptide of type I collagen (PINP), serum carboxyterminal propeptide of type I collagen (ICTP), bone alkaline phosphatase (BAP), osteocalcin (OC), and bone resorption: C-terminal telopeptide of type 1 collagen (I-CTX), N-terminal telopeptide of type 1 collagen (I-NTX), pyridinolines (DPD and PYD), and tartrate-resistant acid phosphatase (TRAP). Bone resorption can be seen either in periarticular bone (demineralization and erosion) or in the total skeleton (osteoporosis). Whatever the location, bone resorption results from activation of osteoclasts when the ratio between osteoprotegerin and receptor activator of nuclear factor kappa-B ligand (OPG/RANKL) is decreased under influence of various proinflammatory cytokines. Bone remodeling markers also allow physicians to evaluate the effect of drugs used in RA like biologic agents, which reduce inflammation and exert a protecting effect on bone. We will discuss in this review changes in bone markers remodeling in patients with RA treated with biologics.Show less >

Language :

Anglais

Popular science :

Non

Collections :

Marrow Adiposity & Bone Lab (MABLab) - ULR 4490

Source :

Harvested from HAL

Files

484280.pdf
Open access
Access the document

document
Open access
Access the document

484280.pdf
Open access
Access the document

Bone Remodelling Markers in Rheumatoid Arthritis BibTeX CSV Excel RIS

Files

Bone Remodelling Markers in Rheumatoid Arthritis

BibTeX

CSV

Excel

RIS